Compound News and Research

RSS

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Emergent BioSolutions today announced the initiation of a Phase I clinical trial for NuThraxTM, also known as AV7909, with the dosing of the first subject.

27 Dec 2010

Growth hormone may be hazardous for middle aged and older people

A compound which acts in the opposite way as growth hormone can reverse some of the signs of aging, a research team that includes a Saint Louis University physician has shown. The finding may be counter-intuitive to some older adults who take growth hormone, thinking it will help revitalize them.

24 Dec 2010

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Teva Pharmaceutical Industries Ltd. announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS).

24 Dec 2010

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data's highly selective adenosine A2A agonist, ATL313, for the indication of primary open angle glaucoma and ocular hypertension.

From Santen Pharmaceutical Co., Ltd. 23 Dec 2010

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.

23 Dec 2010

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia.

23 Dec 2010

Merrion, Novo Nordisk enter Collaboration and Option agreement for GIPET technology

Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the signing of a Collaboration and Option agreement with Novo Nordisk. The agreement will evaluate the ability of Merrion's patented GIPET® technology to boost the oral bioavailability of an undisclosed proprietary compound.

22 Dec 2010

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Anavex Life Sciences Corp. announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Dec 2010

Biomagnification of nanomaterials in simple food chain demonstrated

An interdisciplinary team of researchers at UC Santa Barbara has produced a groundbreaking study of how nanoparticles are able to biomagnify in a simple microbial food chain.

21 Dec 2010

Wellcome Trust awards additional £390,000 for investigation of Allergen Delivery Inhibitors

Scientists at St George's, University of London and the University of Manchester have received an additional Seeding Drug Discovery award of £390,000 from the Wellcome Trust to explore a new class of experimental drugs that block the trigger of allergic reactions before symptoms show.

21 Dec 2010

Recent study finds racial and ethnic minority smokers of menthol cigarettes have lower quit rate

Menthol cigarettes may be harder to quit, particularly for some teens and African-Americans, who have the highest menthol cigarette use, according to a study by a team of researchers.

21 Dec 2010

Rexahn granted Japanese patent for preclinical compound RX-0047

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it was awarded patent 4,546,454 entitled, "Antisense Oligonucleotides that Inhibit Expression of HIF-1," by the Japanese Patent Office.

20 Dec 2010

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

20 Dec 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Arrowhead Research Corporation today announced that it has executed an exclusive world-wide license on technology developed by Drs. Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions, and that it has launched a new company, Ablaris Therapeutics Inc., to commercialize this platform.

20 Dec 2010

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders, which is being conducted in collaboration with Pfizer. As previously reported, the companies recently selected a candidate compound to advance into further clinical studies. Dosing of this candidate compound has now been initiated in a Phase I study in healthy volunteers.

20 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

RXi's dermal anti-scarring candidate selected to advance into development

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.

20 Dec 2010

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

The Muscular Dystrophy Association today announced it has awarded $1.4 million in new research funding to the biopharmaceutical firm Repligen of Waltham, Mass., to complete the preclinical work needed to begin human clinical trials of a promising therapeutic compound for spinal muscular atrophy (SMA).

17 Dec 2010

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

Compound News and Research

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Emergent initiates AV7909 Phase I trail for Anthrax vaccine

Growth hormone may be hazardous for middle aged and older people

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Santen files IND for Clinical Data's ATL313 for primary open angle glaucoma and ocular hypertension

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Merrion, Novo Nordisk enter Collaboration and Option agreement for GIPET technology

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Biomagnification of nanomaterials in simple food chain demonstrated

Wellcome Trust awards additional £390,000 for investigation of Allergen Delivery Inhibitors

Recent study finds racial and ethnic minority smokers of menthol cigarettes have lower quit rate

Rexahn granted Japanese patent for preclinical compound RX-0047

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Exciting progress made in MS research during 2010

RXi's dermal anti-scarring candidate selected to advance into development

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News